Rapid Point-of-care Bacteriuria and Microbial Susceptibility for Women With Suspected Uncomplicated Urinary Tract Infections: Diagnostic Accuracy in General Practice.
Launched by WUERZBURG UNIVERSITY HOSPITAL · Oct 2, 2024
Trial Information
Current as of July 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new testing method for diagnosing urinary tract infections (UTIs) in women. If you are a woman aged 18 or older and have symptoms of a bladder infection—like burning when you urinate, lower abdominal pain, or a frequent urge to go—this study might be for you. Participants will provide a urine sample that will be tested using a rapid system called PA-100-AST, which can quickly find bacteria that cause UTIs and suggest which antibiotics could be effective. Additionally, your sample will also be sent to a lab for a traditional culture test, which is considered the most accurate way to diagnose a UTI. The goal is to see how well the new test works compared to the lab test in a general practice setting.
To be eligible, you should be a female over 18, and your doctor should suspect you have a UTI. However, women with certain conditions, like a urinary catheter, severe urinary tract problems, or those who are pregnant, are not eligible to participate. If you join the study, you can expect a simple urine test and to help researchers understand how this new testing method can improve UTI diagnosis and treatment.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female sex
- • Age 18 or older
- • Clinically suspected UTI according to the general practitioner
- Exclusion Criteria:
- • Urinary catheter
- • Severe urinary tract abnormality (such as cancer or strictures)
- • Immunosuppression (such as chronic immunosuppressant use or AIDS)
- • Dementia or any other condition (including insufficient knowledge of the German language) that could affect informed consent
- • Known pregnancy
About Wuerzburg University Hospital
Würzburg University Hospital, a leading academic medical center in Germany, is dedicated to advancing healthcare through innovative research and clinical trials. As a prominent institution within the University of Würzburg, it combines cutting-edge scientific inquiry with comprehensive patient care. The hospital is committed to improving medical outcomes by fostering collaboration among multidisciplinary teams and leveraging state-of-the-art facilities. With a focus on translating research findings into practical applications, Würzburg University Hospital plays a pivotal role in driving medical advancements and enhancing patient quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Würzburg, Bavaria, Germany
Jena, Thuringia, Germany
Patients applied
Trial Officials
Ildikó Gágyor, MD,Professor
Principal Investigator
University Hospital Wuerzburg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported